Well, so much for chromium...
http://care.diabetesjournals.org/cgi/co ... t/29/3/521
Paper in March isssue of Diabetes Care:
Nanne Kleefstra, Sebastiaan T. Houweling, Frank G.A. Jansman, Klaas H. Groenier, Rijk O.B. Gans, Betty Meyboom-de Jong, Stephan J.L. Bakker, and Henk J.G. Bilo
Diabetes Care 2006 29: 521-525.
OBJECTIVE—Chromium treatment has been reported to improve glycemic control and insulin sensitivity in specific populations of patients with type 2 diabetes. The aim of this study was to determine the effect of chromium treatment on glycemic control in a Western population of insulin-dependent patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—In this 6-month double-blind study, patients with an HbA1c (A1C) >8% and insulin requirements of >50 units/day were randomly assigned to receive treatment with placebo or 500 or 1,000 µg chromium daily in the form of chromium picolinate. The primary efficacy parameter was a change in A1C. Secondary end points were changes in lipid profile, BMI, blood pressure, and insulin requirements.
RESULTS—In this per-protocol analysis (n = 46), the decrease in A1C was approximately equal across the three groups (0.4%). All patients had a BMI >25 kg/m2. No differences were found in the secondary end points. We found a weak relationship between an increasing serum chromium concentration and improvement of the lipid profile.
CONCLUSIONS—There is no evidence that high-dose chromium treatment is effective in obese Western patients with type 2 diabetes.